Kidney Cancer Diagnostics and Therapeutics Global Market Report 2024

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including advancements in molecular biology research, the progress of clinical trials and drug development, innovations in surgical techniques, discoveries in the field of genetics, and improvements in healthcare access.

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to various factors, including advancements in biomarker research, progress in genomic sequencing, the increased adoption of telemedicine and remote consultations, advancements in precision medicine, and the development of rapid diagnostic technologies. Notable trends expected in the forecast period encompass the integration of palliative care, the expansion of long-term survivorship care, interventions focusing on nutrition and lifestyle, an increased role of radiomics, and the adoption of liquid biopsies.

The anticipated rise in kidney cancer prevalence is poised to be a driving force behind the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer, characterized by abnormal changes in normal kidney cells leading to uncontrolled growth and the formation of renal cortical tumors, necessitates effective diagnostics and therapeutics for optimal disease management. These components offer several advantages, including early detection, precise diagnosis, personalized medicine, and treatment monitoring. As per the American Society of Clinical Oncology (ASCO) in March 2023, it is estimated that 81,800 individuals in the United States will be diagnosed with kidney cancer in 2023, with a global impact of 431,288 cases in 2020. Consequently, the increasing prevalence of kidney cancer is expected to foster the growth of the kidney cancer diagnostics and therapeutics market.

The expansion of the kidney cancer diagnostics and therapeutics market is being propelled by the escalation in healthcare spending. Healthcare spending, representing the total financial resources allocated to the healthcare sector, is crucial for addressing the diagnostic and therapeutic needs of kidney cancer. Increased spending ensures early detection, effective treatment, and enhanced patient outcomes, contributing to overall health improvements and mitigating long-term healthcare costs. According to the American Medical Association in March 2023, healthcare spending in the United States witnessed a 2.7% increase in 2021, reaching $4.3 trillion or $12,914 per capita. Thus, the rise in healthcare spending is a key driver of the kidney cancer diagnostics and therapeutics market.

A notable trend gaining traction in the kidney cancer diagnostics and therapeutics market is the approval of innovative products. Major companies in this market are dedicated to developing groundbreaking products to fortify their market positions. For instance, in July 2021, Merck & Co., Inc. secured Health Canada's approval for KEYTRUDA (pembrolizumab) to treat patients with intermediate-high or substantial risk of renal cell carcinoma (RCC) recurrence following nephrectomy. KEYTRUDA, a humanized monoclonal antibody, blocks the programmed death ligand 1 (PD-L1) protein on tumor cells, preventing the immune system from attacking the cancer. This marks a significant advancement in renal cell carcinoma (RCC) treatment, offering benefits such as tumor reduction, slowed cancer growth, and improved quality of life.

Leading companies in the kidney cancer diagnostics and therapeutics market are placing a strong emphasis on the development of innovative products, exemplified by SUTIB, aimed at addressing kidney cancer. SUTIB represents the generic version of Sunitinib, an oral medication recognized for its efficacy in treating certain types of cancer. In a notable example, in February 2021, Glenmark Pharmaceuticals Limited, a prominent pharmaceutical company based in India, successfully launched SUTIB, the generic counterpart of Sunitinib oral capsules, specifically for the treatment of kidney cancer in the Indian market. This introduction is anticipated to provide a more accessible and cost-effective treatment option for patients diagnosed with kidney cancer.


In August 2021, Illumina Inc., a biotechnology company based in the United States, acquired GRAIL for an undisclosed amount. This strategic acquisition aims to expedite the development and commercialization of GRAIL's galleri, a multi-cancer early-detection test, enhancing patient access to life-saving diagnostic services for kidney cancer and other malignancies. GRAIL, a biotechnology company specializing in cancer diagnostics, holds significance for its contribution to early disease detection.

Major companies operating in the kidney cancer diagnostics and therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited


North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of kidney cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) is the predominant type, accounting for the majority of kidney cancer cases. RCC is further categorized into various subtypes based on the microscopic appearance of cancer cells. Kidney cancer diagnostics and therapeutics play a crucial role in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Treatment involves the use of components such as drugs and diagnostics, with diagnostics including biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram, and ultrasound. Therapies for kidney cancer include targeted therapy, immunotherapy, and chemotherapy. The main end-users of these diagnostics and therapeutics are hospitals, pharmaceutical labs, and genomic laboratories.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, kidney cancer diagnostics and therapeutics market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.